Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy Journal Article
| Authors: | Yossepowitch, O.; Eggener, S. E.; Serio, A. M.; Carver, B. S.; Bianco, F. J. Jr; Scardino, P. T.; Eastham, J. A. |
| Article Title: | Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy |
| Abstract: | Objectives: Commonly used definitions for high-risk prostate cancer identify men at increased risk of PSA relapse after radical prostatectomy (RP). We assessed how accurately these definitions identify patients likely to receive secondary cancer therapy, experience metastatic progression, or die of prostate cancer. Materials and methods: Among 5960 men with clinically localized or locally advanced prostate cancer who underwent RP, we identified eight different high-risk subsets, each comprising 4-40% of the study population. Estimates of freedom from radiation therapy, hormonal therapy, and metastatic progression after surgery were generated for each high-risk cohort with the Kaplan-Meier method, and hazard ratios (HR) were calculated with a Cox proportional hazards regression. The cumulative incidence and HR for prostate cancer-specific mortality (PCSM) were estimated with competing risk analysis. Results: Each of the studied high-risk criteria was associated with increased hazard of secondary cancer therapy (HR = 1.3-5.2, p < 0.05) and metastatic progression (HR = 2.1-6.9, p < 0.05). However, depending on the definition, the probability of freedom from additional therapy 10 yr after surgery ranged from 35% to 76%. The 10-yr cumulative incidence of PCSM in high-risk patients ranged from 3% to 11% (HR = 3.2-10.4, p < 0.0005). Conclusions: Commonly used definitions for high-risk prostate cancer identify men at increased risk of secondary cancer therapy, metastatic progression, and PCSM following RP. However, a substantial proportion of high-risk patients remain free from additional therapy or metastatic disease many years after surgery. The risk of PCSM within 10 yr of treatment is remarkably low, even for patients at the highest risk of recurrent disease. © 2007 European Association of Urology. |
| Keywords: | treatment outcome; survival rate; retrospective studies; major clinical study; advanced cancer; cancer growth; antineoplastic agents; united states; cancer patient; radiotherapy, adjuvant; follow-up studies; cancer incidence; neoplasm staging; metastasis; risk factors; high risk patient; time factors; risk assessment; cancer hormone therapy; prostate cancer; prostatic neoplasms; prostatectomy; disease progression; neoplasm metastasis; radical prostatectomy; cancer relapse; radiation therapy; hormonal therapy; metastatic progression; prostate cancer-specific mortality |
| Journal Title: | European Urology |
| Volume: | 53 |
| Issue: | 5 |
| ISSN: | 0302-2838 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2008-05-01 |
| Start Page: | 950 |
| End Page: | 959 |
| Language: | English |
| DOI: | 10.1016/j.eururo.2007.10.008 |
| PUBMED: | 17950521 |
| PROVIDER: | scopus |
| PMCID: | PMC2637146 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 34" - "Export Date: 17 November 2011" - "CODEN: EUURA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work